Latest News and Press Releases

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

Dublin, June 30, 2025 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics Including Executive/Consultant Guides and Customized Forecasting/Analysis" report has been added to ...

Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Interleukin-2 Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's...

NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...

Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American...

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Tecentriq (Atezolizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...

NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...

Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Interleukin-2 - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancerRecently announced positive final...